Sagimet Biosciences advances AURORA U.S. Phase 3 denifanstat trial
Sagimet Biosciences advances its AURORA U.S. Phase 3 trial of denifanstat in acne toward patient enrollment in Q4 2026.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Sagimet Biosciences advances its AURORA U.S. Phase 3 trial of denifanstat in acne toward patient enrollment in Q4 2026.